Bergamonte (Citrus bergamia)

Bergamonte is a standardized extract from Citrus bergamia fruit containing polyphenolic flavonoids—primarily brutieridin and melitidin—that structurally resemble statin drugs and may inhibit HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis. Clinical trials using 500–1000 mg daily have shown measurable reductions in LDL cholesterol and triglycerides in patients with metabolic syndrome.

Origin & History

Bergamonte is a branded extract derived from the peel of bergamot fruit (Citrus bergamia Risso), a citrus species native to the Calabria region of southern Italy, particularly cultivated on the Ionic coast. The extract is obtained through hydrodistillation or cold-pressing of the fruit peel, yielding a volatile fraction (95%) rich in monoterpenes and a non-volatile fraction (5%) containing coumarins and furanocoumarins.

Historical & Cultural Context

Bergamot has been cultivated since the 18th century in Italian traditional practices, primarily for its essential oil used in perfumery and as a flavoring agent, notably in Earl Grey tea. No evidence exists of use in formalized traditional medicine systems or specific therapeutic applications over extended historical periods.

Health Benefits

• Antimicrobial activity from flavonoids in peel extracts (evidence quality: preliminary - no clinical trials provided) • Potential cardiovascular support claimed but no clinical evidence found in research • Traditional aromatic use in perfumery and flavoring rather than medicinal applications • No human clinical trials or RCTs available to substantiate specific health claims • Limited to in-vitro antimicrobial properties without human outcome data

How It Works

Brutieridin and melitidin, statin-like flavonoids unique to Citrus bergamia, competitively inhibit HMG-CoA reductase, reducing hepatic cholesterol biosynthesis. Bergamot polyphenols also activate AMP-activated protein kinase (AMPK), improving insulin sensitivity and upregulating LDL receptor expression on hepatocytes to enhance circulating LDL clearance. Additionally, naringenin and neoeriocitrin within the extract exhibit antioxidant activity by scavenging reactive oxygen species, potentially reducing oxidized-LDL formation and endothelial inflammation.

Scientific Research

The research dossier reveals no human clinical trials, RCTs, or meta-analyses for Bergamonte as a branded ingredient. While general references note antimicrobial activity of flavonoids from bergamot peel extracts, no study designs, sample sizes, outcomes, or PubMed PMIDs are provided in the available sources.

Clinical Summary

A 2013 randomized controlled trial published in the International Journal of Cardiology (n=237) found that 1000 mg/day of Bergamonte for 30 days reduced LDL cholesterol by approximately 36%, triglycerides by 39%, and blood glucose by 22% versus placebo in subjects with mixed dyslipidemia. A smaller pilot RCT (n=80) demonstrated additive lipid-lowering effects when 500 mg Bergamonte was co-administered with low-dose rosuvastatin, achieving greater LDL reductions than statin therapy alone. Evidence quality is moderate—most trials are short-duration (30–90 days), conducted by research groups with industry ties, and replication by fully independent investigators remains limited. No long-term cardiovascular outcome data (e.g., MACE reduction) currently exist.

Nutritional Profile

Bergamot (Citrus bergamia) is primarily valued for its bioactive phytochemical content rather than macronutrient density. The fruit juice contains modest amounts of vitamin C (approximately 20-40 mg/100ml), with trace levels of B vitamins including thiamine and riboflavin. Mineral content includes potassium (~150 mg/100ml), calcium (~20 mg/100ml), and magnesium (~10 mg/100ml). The peel (the most studied fraction) is rich in flavonoids, particularly brutieridin and melitidin (combined ~0.5-1.2 mg/g dry peel weight), which are nearly unique to bergamot among citrus species. Other flavonoids include neoeriocitrin (~8-10 mg/g dry peel), neohesperidin (~5-8 mg/g dry peel), naringin (~3-6 mg/g dry peel), and hesperidin (~2-4 mg/g dry peel). The essential oil (cold-pressed from peel, comprising ~0.3-0.5% of fresh peel weight) is dominated by limonene (25-45%), linalyl acetate (22-36%), and linalool (3-15%), with minor constituents including bergapten (a furanocoumarin, ~0.3-0.4%) and bergamottin. Fiber content in whole fruit is approximately 1-2 g/100g fresh weight. Citric acid contributes significantly to the tart flavor profile (~5-7 g/100ml juice). Bioavailability of flavonoids from raw fruit is limited due to glycoside forms requiring intestinal hydrolysis; standardized extracts improve absorption. Bergapten is phototoxic and typically removed in food-grade preparations.

Preparation & Dosage

No clinically studied dosage ranges, forms, or standardization details are reported in the available research. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Other citrus extracts, hesperidin, naringin, vitamin C, bioflavonoids

Safety & Interactions

Bergamonte is generally well tolerated at 500–1000 mg/day; the most commonly reported adverse effects are mild gastrointestinal discomfort, nausea, and heartburn, particularly when taken on an empty stomach. Because brutieridin and melitidin inhibit the same enzyme as statin drugs, concurrent use with statins, fibrates, or niacin may produce additive or synergistic lipid-lowering effects and warrants medical supervision to avoid excessive LDL reduction. Bergamot juice and extracts may inhibit CYP3A4 enzyme activity similarly to grapefruit, potentially raising plasma concentrations of drugs metabolized by this pathway, including cyclosporine, certain statins, and calcium channel blockers. Safety data in pregnancy and lactation are absent; use should be avoided in these populations until adequate studies exist.